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Abstract
The molecular pathogenesis of chronic lymphoproliferative disorder of natural killer (NK) cells (CLPD‐NK) is poorly
understood. Following the screening of 57 CLPD-NK patients, only five presented STAT3 mutations. WES profiling of 13
cases negative for STAT3/STAT5B mutations uncovered an average of 18 clonal, population rare and deleterious
somatic variants per patient. The mutational landscape of CLPD-NK showed that most patients carry a heavy
mutational burden, with major and subclonal deleterious mutations co-existing in the leukemic clone. Somatic
mutations hit genes wired to cancer proliferation, survival, and migration pathways, in the first place Ras/MAPK, PI3K-
AKT, in addition to JAK/STAT (PIK3R1 and PTK2). We confirmed variants with putative driver role of MAP10, MPZL1,
RPS6KA1, SETD1B, TAOK2, TMEM127, and TNFRSF1A genes, and of genes linked to viral infections (DDX3X and RSF1) and
DNA repair (PAXIP1). A truncating mutation of the epigenetic regulator TET2 and a variant likely abrogating PIK3R1-
negative regulatory activity were validated. This study significantly furthered the view of the genes and pathways
involved in CLPD-NK, indicated similarities with aggressive diseases of NK cells and detected mutated genes targetable
by approved drugs, being a step forward to personalized precision medicine for CLPD-NK patients.
Introduction
Among the abnormal proliferations of large granular
lymphocytes (LGL), chronic lymphoproliferative disorder
of natural killer (NK) cells (CLPD‐NK) is characterized by
a persistent (>6 months) clonal expansion of LGL of the
NK lineage1 in the peripheral blood with an absolute NK-
LGL count ≥0.5 × 109/L. CLPD‐NK patients are generally
asymptomatic, with a minority of cases presenting with
cytopenia, mainly neutropenia and anemia. CLPD‐NK is
commonly associated with autoimmune disorders and
neoplastic conditions, both hematological and non-
hematological. The clinical course of CLPD-NK is
usually indolent, consistent with the better characterized
T-cell LGL leukemia (T-LGLL), whereas it is clearly dis-
tinguished from the aggressive NK cell leukemia (ANKL)
and extranodal NK/T-cell lymphoma-nasal type
(NKTCL). CLPD-NK is often characterized by a CD3−
CD16+ CD56+ CD8± CD57± phenotype and a restricted
pattern of killer immunoglobulin-like receptors (KIR)
providing a surrogate marker of clonality2.
Evidence on the genomic landscape of T-LGLL pointed
to a key role of somatic mutations within JAK/STAT
(mostly in STAT3 and STAT5B genes) and Ras/MAPK
pathways3–10. In ANKL and NKTCL, JAK2 and STAT3
mutations, lesions of epigenetic modifiers and tumor
suppressors were detected11–13. Only scattered data are
available on the molecular features underlying CLPD-NK,
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mainly provided by approaches targeted to exons of spe-
cific genes, with limited discovery power. STAT3 muta-
tions were almost all identified in exons 20–21 encoding
the Src homology 2 domain, with different prevalence in
different cohorts7,14–16. Albeit relatively rare, STAT3
mutations are regarded as a diagnostic tool, in addition to
the aberrant NK-cell immunophenotype and bone mar-
row or splenic infiltration by cytotoxic lymphocytes14.
CLPD-NK patients with STAT3 mutations often require
treatment and STAT3 mutations have been found to
correlate with a CD3− CD16+ CD56dim CD57− immu-
nophenotype16 and cytopenias, such as anemia15 or severe
neutropenia16. STAT5B, a gene essential for NK cell
biology17 and frequently mutated in CD4+ T-LGL leu-
kemia18, has been found mutated only in one patient
diagnosed with CLPD-NK (3%), who later progressed to
ANKL9. Somatic mutations in few other genes of the JAK/
STAT pathway, such as JAK3 (10%)14, and of the NF-
kappa B signaling pathway, such as TNFAIP3 (6%)15, were
seldom detected in CLPD-NK.
The fact that STAT3 mutations were found only in a
minority of CLPD-NK patients, and the observation of
STAT3 activation and increased expression of genes
activated by STAT3 also in patients with wild-type
STAT37 encouraged investigation of the CLPD-NK
genetic profile of patients resulting negative after
screening for STAT3 and STAT5B mutations. CLPD-NK
positioning relatively to T-LGLL, ANKL, and NKTCL, is
unclear and CLPD-NK maintained a provisional status in
the last 2017 WHO classification. Large studies informing
CLPD-NK molecular profiling are still lacking and, in this
regard, CLPD-NK remains a poorly characterized disease.
Key open questions include CLPD-NK etiopathogenesis
and molecular features underlying patient heterogeneity
and possibly indicating targetable lesions.
In the present study of a sizeable CLPD-NK patient
cohort, a low prevalence of STAT3 mutations was con-
firmed and no STAT5B mutations were detected,
prompting a deep WES analysis of the largest so far group
of patients with CLPD-NK. All the considered patients
had wild-type STAT3 and STAT5B at screening. We
disclosed still unexplored aspects of the molecular land-
scape of CLPD‐NK, finding mutations of genes wired to
cancer proliferation, survival, and migration pathways and
potential driver genes for which FDA-approved drugs are
available.
Material and methods
Patients
A cohort of 57 CLPD-NK patients was recruited at the
Hematology Unit of Padua University Hospital. The study
and blood sample collection were approved by the Ethic
Committee for Clinical Trials of Padua. The diagnosis
followed WHO criteria (LGL count over 0.5 × 109/L
persisting for at least six months and CD3− CD16+ CD8
± CD57± CD56± phenotype). Six of the patients con-
sidered in the study received treatment. Analyzed DNA
was collected at diagnosis. Clinical data, including sex,
age, presence of cytopenia and mutational status on
STAT3/STAT5B genes were collected for each patient.
According to the Helsinki Declaration, patients gave
written informed consensus prior to inclusion in
the study.
STAT3 and STAT5B mutation screening
DNA from purified leukemic clones of 57 CLPD-NK
patients was screened for mutations in hotspot regions of
STAT3 and STAT5B genes, by Sanger sequencing or by
Amplification Refractory Mutation System (ARMS)
polymerase chain reaction (PCR).
For Sanger sequencing, DNA was amplified with pri-
mers9,10 (Supplementary Table 1) covering exons 19–21
for STAT3 and exon 16 for STAT5B genes. Purified PCR
products were sequenced using dye terminator technology
and ABI 3130 sequencer (Applied Biosystem); Sequencing
results were analyzed with ChromasPro software.
ARMS PCR was performed using outer primers to
amplify the target region of STAT3 gene and inner primer
pairs to selectively amplify the variant (Y640F or D661Y7)
or the wild-type allele.
WES profiling
Ten representative CLPD-NK patients (Table 1) were
selected for WES according to their immunophenotype,
clinical features, and absence of STAT3/STAT5B muta-
tions, determined by Sanger sequencing (Supplementary
Table 1).
Mononuclear cells (MC) and granulocytes were isolated
from peripheral blood (PB) of CLPD-NK patients using
Lymphocytes Separation Media (Biowest). NK cells were
purified from PBMC using magnetic Micro-Beads coated
with monoclonal anti-human CD57, CD56, or CD16
antibodies (Miltenyi Biotec), according to the dominant
leukemic population. At least 97% purity of both NK
leukemic cells and granulocytes (control sample) was
confirmed by flow cytometry analysis. Contamination of
monocytes in the residual fraction resulted below 1% in all
samples.
DNA was extracted using Puregene cell and tissue kit
(Qiagen). WES (Illumina platform, Agilent SureSelect
60Mbp kit with paired end reads) was performed starting
from 1 µg of DNA from both tumor and control samples
for each patient.
Somatic variant detection and prioritization
The study cohort (Table 1) of 13 patients comprised ten
newly sequenced and three previously profiled by WES
and analyzed with a different pipeline3.
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WES data of tumor-control matched samples were
analyzed by using an in-house made pipeline based on
Docker19 which automatically performs bioinformatics
analysis, from reads alignment to somatic variant
calling and annotation (Supplementary Fig. 1). Somatic
single-nucleotide polymorphisms (SNPs) and
insertions/deletions (indels) were detected with three
different variant callers to increase the discovery
power: MuTect20, MuTect221, and Strelka222. Only
variants called in regions with coverage of at least ten
reads were kept.
Somatic variants with population allele frequency >5%
were discarded, considering gnomAD (Genome Aggre-
gation Database, https://gnomad.broadinstitute.org) data
of non-Finnish European and Finnish populations for the
analysis of patients from Italy and Finland, respectively.
Next, known variants were associated with dbSNP
(v. 151)23 or COSMIC (v. 84)24 identifiers and those
annotated as benign or likely benign in ClinVar (updated
on 23/07/2018) were discarded. Only variants with
SnpEff25 predicted impact HIGH or MODERATE and
with MetaSVM26 predicted impact “deleterious” were
further considered.
Mutated gene network analysis
R Graphite Bioconductor package (v.1.28.2)27 was
used to convert KEGG28 and Reactome29 pathway
topologies into pathway-derived mutated gene net-
works, using appropriate biology-driven rules to trans-
form different types of direct and indirect relations
between genes and gene products annotated in pathways
(i.e., regulatory relations, participation to molecular
complexes, and biosynthetic pathways, also with com-
pound intermediates) into pairwise connections
between genes. Pathways including at least one mutated
gene were converted into networks and merged in order
to build up a unique nonredundant KEGG-Reactome
meta-network. The meta-network was integrated also
with protein–protein interactions derived from Reac-
tome FI30. Genes with normalized expression lower than
1 in Human Protein Atlas (https://www.proteinatlas.
org/) were not considered, finally depicting 43 pairwise
direct, indirect and predicted interactions between 44
genes. The possible driver role of mutated genes was
evaluated considering prediction made by Cancer Gen-
ome Interpreter31 (www.cancergenomeinterpreter.org),
variant allele frequency (VAF) and impact on protein
and gene function. Visualization, optimization and
annotation of the network were performed using
Cytoscape v3.5.132.
Variant validation
DNA from both purified leukemic clone and autologous
granulocytes was analyzed to confirm the presence of the
tested mutation only in the tumor counterpart. Variants
were confirmed by Sanger sequencing (VAF at least 0.2)
or ARMS PCR. Custom primers (Supplementary Table 1)
were designed by Primer3, using GRCh37.p13 as refer-
ence, analyzed with IDT OligoAnalyzer Tool and obtained
from Sigma-Aldrich.
Table 1 Clinical and molecular features of the 13 CLPD-NK patients analyzed by WES.
CLPD-NK Pat. Sex Age WBC ANC Hb PLT ALC Immunophenotype KIR expression restricted NKG2
76 M 45 6.4 2.5 147 300 4.96* CD16+ CD56+ CD57+ 158B C
100 M 52 10 2.36 151 227 9.12* CD16+ CD56+ CD57+ 158E A
115 M 79 7 2.2 144 163 3.76* CD16+ CD56+ CD57+ 158B Negative
117 M 49 7.1 2.67 155 245 5.24* CD16+ CD56+ CD57+ 158B A
165 M 43 3.16* 1.32* 153 60* 1.90 CD16+ CD56+ CD57− Not expressed A
187 M 73 5.16 1.94 159 198 8.89* CD16+ CD56− CD57+ Not expressed A
260 M 59 12.35* 1.31* 133 238 9.95* CD16+ CD56+ CD57+ Not expressed A
337 M 67 5.6 2.53 147 217 4.42* CD16+ CD56+ CD57+ 158A A
448 M 59 5 3.98 88* 317 4.15* CD16+ CD56+ CD57+ Not expressed A
452 M 44 6.4 2.29 145 207 5.31* CD16+ CD56− CD57+ 158B A
1253 F 65 4.1 0.01* 120* 157 3.35 CD16+ CD56− CD57+ NA NA
1272 F 47 7.7 NA NA NA NA CD16+CD56− CD57+ NA NA
1260 F 46 10.9 1.49* 114* 281 10.89* CD16+ CD56− CD57+ NA NA
All patients resulted wild type for STAT3 and STAT5B (see Methods). *indicates values outside the normal range (WBC 3.5–11 × 109/L; ANC 1.9–5.3 × 109/L; Hb
125–169 g/L; PLT 110–330 × 109/L; ALC 1.18–3.62 × 103/μL). All patients presented restricted KIR expression (either presence of only one KIR or total absence of KIR
expression) and most frequently a heterodimer of the A type NKG2 with CD94+. WBC white blood count, ANC absolute neutrophil count, ALC absolute lymphocyte
count, Hb hemoglobin, PLT platelets, M male, F female, NA not available.
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Results
STAT3 and STAT5B mutations are rare in CLPD-NK patients
The collected study group of 57 CLPD-NK patients
(Supplementary Table 2) included the 25 cases previously
screened for STAT3 exon 21 and STAT5B exon 16 muta-
tions16. All patients were diagnosed for CLPD-NK at the
Hematology Unit of Padua University Hospital, from 2000 to
2019, and underwent routine immunophenotyping and
molecular characterization, based on PBMC samples. The
median age at diagnosis was 68 years, with a prevalence of
male patients (82%). Abnormal white blood count, absolute
neutrophil count (ANC), or hemoglobin level were recorded
in 14% of patients, whereas only 4% of them had low count of
platelets. Immunophenotypic analysis revealed that CD16+
CD56+ CD57+ expression, with a restricted pattern of KIR
expression and CD94+ NKG2A+ heterodimer, was the
most frequent among the cohort. Six patients (10.5%)
underwent treatment, mostly related to the development of
autoimmune hemolytic anemia or symptomatic neutropenia.
STAT3 mutation screening, in exons 19–21, detected
somatic mutations in the SH2 domain only in 5 out of 57
patients studied (9%). Two cases carried Y640F mutation
(detected by Sanger sequencing and ARMS PCR), whereas
D661Y, N647I, and S614R mutations were found in one case
each by Sanger sequencing (Fig. 1). Only two out of the six
patients that required treatment carried STAT3 mutations,
presented neutropenia and CD3− CD16+ CD56dim CD57−
immunophenotype (Supplementary Table 2), in accordance
with Barilà et al.16. The same immunophenotype was asso-
ciated with a normal ANC in a third patient, whereas the last
case had the most common CD3− CD16+ CD56dim CD57+
immunophenotype.
Table 2 Validated somatic variants in CLPD-NK patients.
CLPD-
NK Pat.
Gene Variant VAF Variant effect and involved domain
100 FGF14 p.Thr224Met 0.26 Missense variant close to an acetylation site
100 MAPK8IP3 p.Val1314fs 0.21 Deletion leading to stop codon in 1315 position
100 RPS6KA1* p.Ser430fs 0.4 Frameshift variant in the PKinase domain
115 PIK3R1* p.
Ser565_Ile566insGluTyrArgGluIleAspLysArgMetAsnSer
0.38 In-frame insertion in protein-protein interaction site, predicted to
be oncogenic by OncoKB
115 TAOK2* p.Val244Met 0.25 Missense variant in the PKinase domain
115 TNFRSF1A* p.Pro102Arg 0.34 Missense variant in the cysteine-rich domain important for ligand
binding
117 TMEM127 p.His165Arg 0.12 Missense variant in the loop between transmembrane domains
S3 and S4
165 DDX3× c.104-2 A > G 0.89 Variant in splicing acceptor site of exon3
165 TET2* p.Arg1465* 0.31 Truncating variant in the Oxygenase domain, likely oncogenic loss
of function
165 RXRG* c.623-1 G > C 0.22 Variant in splicing acceptor site of exon 4
165 CFH p.Gly1118Glu 0.37 Missense variant in Sushi domain involved in immune recognition
processes
165 MPZL1 p.Phe60Leu 0.34 Missense variant in V-set Immunoglobulin like domain
165 EFEMP1 p.Arg362* 0.40 Stop gain mutation in EGF like domain eliminating 5
phosphorylation sites
165 SALL1 p.Ala377fs 0.48 Frameshift mutation truncating the protein before all the functional
domains
187 RSF1 p.Val68Met 0.43 Missense variant in the DDT domain involved in DNA binding
260 SETD1B p.Ala889Asp 0.14 Missense variant possibly altering the secondary structure
452 MAP10 p.Leu846* 0.23 Truncating variant in HPHLAWLY domain
452 PAXIP1 p.Gly638Ser 0.25 Missense variant in the phospho-binding BRCT domain
For 18 somatic variants confirmed by Sanger sequencing or ARMS PCR, details about the variant type, VAF, and possible effects are provided; *indicate genes for
which interactions with FDA-approved drug interactions are known (http://www.dgidb.org/).
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None of the patients resulted mutated after screening of
STAT5B exon 16, confirming that STAT5B mutations are
rare in CLPD-NK.
Deleterious somatic variants of the leukemic clone in
CLPD-NK patients detected by WES profiling were
validated
Among the 52 CLPD-NK patients negative for STAT3/
5B mutations, ten with typical immunophenotype,
representative of clinical manifestations (Table 1),
including the two cases who required treatment, under-
went WES profiling (Agilent SureSelect 60Mbp, Illumina
sequencing, paired end reads). For these cases, a highly
purified leukemic clone and normal granulocytes, used as
control, were used for WES.
After WES sequence read quality selection and align-
ment to the reference genome, a high and homogenous
sequence coverage in the cohort was obtained (in average
159× and 142× for tumor and control samples, respec-
tively; over 95% of target regions with coverage of at least
20; Supplementary Fig. 2). Variant calling with different
methods (MuTect20, MuTect221, and Strelka222; Supple-
mentary Fig. 1) detected 5124 SNPs and 119 indels with
high confidence in the whole cohort. We excluded a sig-
nificant correlation between the number of somatic var-
iants and the mean coverage in tumor and in control
samples (Supplementary Figure 3).
Next, variant annotation, filtering and analysis were
conducted leveraging several software tools and databases
(see the Methods section and Supplementary Figure 1).
Briefly, known variants (in dbSNP and COSMIC) likely
benign according to ClinVar, and/or with population allele
frequency >5% (according to gnomAD) were discarded to
focus on possible driver genes. To this aim, among the
remaining variants, only those predicted to be “very dele-
terious” both according to SnpEff25 and MetaSVM26 were
further considered. Thus, 867 variants (in 827 genes) rare in
the reference population and also predicted to be deleter-
ious by different methods were kept.
Somatic mutations with different VAF were detected in
the leukemic samples (Supplementary Fig. 4). The VAF
distribution was heterogeneous in different patients
(Kruskal–Wallis test, p value= 2.2e−16), and overall 80%
of variants had VAF lower than 0.05 in the NK leukemic
cells; a very high (>97%) purity of these cells had been
confirmed by flow cytometry analysis.
In addition, three CLPD-NK patients negative for STAT3/
STAT5B mutations and previously profiled by WES3 were
included in the study (Table 1). WES data of these patients
were reanalyzed with the same computational pipeline and
criteria used for newly sequenced samples.
In the 13 CLPD-NK patients altogether, 235 deleterious
somatic variants (217 SNPs and 18 indels, in 226 genes;
Supplementary Table 3) present with VAF ≥ 0.05 were taken
to further analysis, also considering the purity level. From 13
to 37 deleterious variants in different genes coexisted (Fig.
2a), with 6 genes recurrently mutated in the cohort (Fig. 2b).
Figure 2c shows in more detail, for each patient, which and
how many genes carried deleterious variants with VAF > 0.1,
that we considered more likely to include the genes playing a
role in the disease. Eighteen of these somatic variants with
VAF > 0.1 were prioritized for validation according to variant
type and particularly to gene function. Sanger sequencing or
ARMS PCR, when the VAF was below 0.2, confirmed all the
tested variants (Table 2, Supplementary Fig. 5). For several
patients, validation of multiple co-occurring variants was
obtained.
Mutations of genes of the JAK/STAT pathway are not
common in CLPD-NK
In all the samples, WES profiling gave high coverage for
STAT3, STAT5B, JAK3, and TNFAIP3, genes previously
associated with the disease. Negativity for STAT3 and
STAT5B mutations in the 10 CLPD-NK patients, pre-
viously screened for mutations in the hotspot regions of
these genes, was confirmed by WES, for all patients,
including the two cases (#187 and 448) who required
treatment afterwards. Patient #187 presented 6 different
variants at high VAF; among these, RSF1, encoding a
protein involved in the transcription of hepatitis B virus
genes, was validated. On the contrary, patient #448 pre-
sented all the variants with a VAF lower than 0.2. Neither
JAK3, found mutated in CLPD-NK by Kurt et al.14, nor
other JAK genes, were mutated in our cohort.
Provided the reported prevalence and driving role of
STAT3mutations7 in CLPD-NK and the previous findings of
mutations of the STAT protein interactor FLT3 in a T-LGLL
patient without STAT lesions3, we searched for mutations in
genes functionally related to JAK/STAT signaling in CLPD-
NK patients, starting from STAT3 and STAT5B interactors
in STRING database: only PTK2/FAK1 was mutated in
patient #1253 (VAF 0.35), as previously reported3. In addi-
tion, only one of the 162 genes annotated in the KEGG JAK/
A B
SH2
aa0771
9%
91%
STAT3 status
Mutated
Wild-type
STAT3
Fig. 1 STAT3 mutations in a cohort of 57 CLPD-NK patients.
a STAT3 was mutated in 5 out of 57 patients (9%). b Four different
variants were observed in the SH2 domain.
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STAT pathway was mutated in the cohort: we confirmed in
patient #115 a deleterious variant in PIK3R1, encoding the
phosphoinositide-3-kinase regulatory subunit 1, predicted to
be a driver loss of function mutation of a known tumor
suppressor gene. PIK3R1 is indeed a pivotal kinase negatively
regulating the catalytic subunit (PIK3CA) of the PI3K com-
plex and antagonized by the tumor suppressor PTEN. PI3K
enzymes, mediating interchange of phosphates on inositol
phospholipid species at the plasma membrane, are respon-
sible for the coordination of a range of cell functions,
including proliferation and survival, and play a prominent
role in natural killer cell biology33. Although PIK3R1 parti-
cipates in several connected signaling pathways, it is also
downstream of JAK signaling, witnessing the interconnec-
tions between JAK/STAT and PI3K signaling34.
The duplication of 11 amino acids at position 565 in the
coiled coil region of the protein was restricted to the
leukemic clone, with VAF 0.38. This PIK3R1 variant
coexisted in patient #115 with mutations of other genes,
all at a lower VAF (Fig. 2c). In summary, 2/13 (15%) STAT
negative patients carried mutations in STAT3 interactors
or other genes annotated in the JAK/STAT pathway.
Fig. 2 Heterogeneity of CLPD-NK patient leukemic clones disclosed multiple clonal and subclonal somatic mutations. a Number of
mutations per patient and b summary of genes recurrently mutated in the cohort, showing different classes of VAF; c prominent genes in each
patient are indicated by radar plots of VAF (only genes with somatic variants with VAF ≥ 0.1 are shown).
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Somatic mutations recurrent in CLPD-NK
Six genes were recurrently mutated in our cohort
(Fig. 2b), five with only subclonal variants (VAF < 0.2).
The transcription factor FOXD4L3 was found mutated in
three patients with VAF ranging from 0.09 to 0.12,
whereas CACNA1D, CFTR, GOLGA6L19, and NBPF1
carried subclonal variants in two CLPD-NK patients.
TET2 (Tet Methylcytosine Dioxygenase 2) tumor sup-
pressor gene carried loss of function variants in two
patients. The validated TET2 variant (p.Arg1465*, VAF
0.31) in patient #165 abolished most of the oxygenase
catalytic domain (aa 1290–1905). In patient #1253 the
frameshift TET2 p.Pro989fs variant (VAF 0.05) leads to a
premature stop codon in 1008 position, before the cata-
lytic domain. Deleterious somatic mutations in a large
series of genes co-occurred with TET2 mutation in
patient #165, including a validated high VAF splicing
variant of DDX3X gene encoding an ATPase/RNA heli-
case of the DEAD-box family, acting in RNA metabolism,
cell cycle control, apoptosis, stress response and innate
immunity.
We considered that deleterious variants in genes not
expressed in NK cells may unlikely be regarded as disease
drivers. Notably, TET2 and NBPF1 genes showed high
expression in normal NK cells, according to the Human
Protein Atlas35 (www.proteinatlas.org) RNA-seq data.
Pathway-derived network of CLPD-NK somatic mutations
Considering 109 genes expressed in NK cells and car-
rying deleterious variants, a data-driven picture of path-
ways and biological functions recurrently hit by somatic
mutations in CLPD-NK patients emerged from the con-
struction of an integrated mutation network based on
KEGG and Reactome pathways and on protein–protein
interactions (Fig. 3a). The 44 genes in the network, and
several others aggregated in seven main biological func-
tions as shown in Fig. 3b. The same figure summarizes
also the most relevant findings for each patient, con-
sidering gene function and expression, mutation VAF,
recurrence, impact on protein, and possible driver role
evaluated by Cancer Genome Interpreter31.
Eleven CLPD-NK patients carried deleterious muta-
tions in at least one of 28 genes participating to Ras/
MAPK or PI3K-AKT signaling pathways, associated
with cancer proliferation, survival, and migration
(Fig. 3b). High VAF and very deleterious variants of
several genes of these signalings (PIK3R1, MPZL1,
RPS6KA1, TAOK2, and TNFRSF1A) were validated
(Table 2) and were likely relevant considering the high
expression of these genes. In addition, five patients
carried also mutations in eight genes linked to viral
infections, including the above mentioned tumor sup-
pressor gene DDX3X that is frequently mutated in
NKTCL12 and in ANKL11, and RSF1 (Table 2). Other
groups of functionally related genes hit in 10/13 (77%)
patients comprised genes regulating cell cycle and DNA
repair, such as CDC25B, PLK2, PAXIP1, and genes
important for immune system functions and/or involved
in Interleukin signaling (GRAP2). TET2 and other epi-
genetic modulators were mutated in 5/13 patients
(38%), including SETD1B whose variant was validated.
Reanalysis of three patients previously studied3 with
refined bioinformatic methods confirmed findings and
uncovered a few additional deleterious variants of pos-
sible relevance (Supplementary Table 3), as BRAF and
TET2 mutations, coexisting at subclonal level with
deleterious variants of PTK2 and KRAS in patient #1253
and NECTIN2 in patient #1260. In most patients, as
confirmed by variant validations (Table 2), multiple
mutations of putative functional importance were
indeed present, often hitting the same functions (Fig. 3).
Discussion
This study disclosed the molecular landscape of somatic
mutations in CLPD‐NK by an exploration of the largest so
far patient cohort analyzed by WES. Even though the
relatively “benign” and indolent nature of the CLPD-NK
disease is well recognized, the number and predicted
impact of somatic variants and functions of mutated
genes detected in this study indicated that the leukemic
clone of CLPD-NK patients carried a heavy burden of
lesions involving genes related to cancer proliferation,
survival and migration. Co-existence in the leukemic
clone of a few major deleterious mutations with subclonal
lesions was also observed. Among clonal mutations, likely
drivers were identified. These results considerably
broaden our view of the genes and pathways frequently hit
in CLPD-NK patients, opening new lines of investigation.
First, the examination of 57 CLPD-NK cases detected
only five patients with mutations in the highly conserved
SH2 domain mediating STAT3 protein dimerization and
activation, triggering transcription of downstream genes.
The low frequency of STAT3 mutations in our cohort and
the absence of STAT5B mutations in the 57 patients
screened in the hotspot regions of these genes was in line
with the complete absence in the cohort of 13 CLPD-NK
analyzed by WES of STAT3 and STAT5B mutations, even
outside the regions covered by the screening. Collectively,
these observations confirmed that the inclusion of
patients negative for STAT3 and STAT5B mutations
enhanced the study discovery power.
Our cohort of 57 patients was characterized by a 9%
prevalence of STAT3 mutations, resulting lower in com-
parison with the 30% prevalence described on 50 CLPD-NK
patients by Jerez et al.7. Even if the clinical diagnosis and
inclusion criteria for CLPD-NK36 patients in the two
cohorts were homogeneous, a lower proportion (14% vs.
60% from Jerez et al.7) of symptomatic patients in our
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cohort can possibly explain the molecular differences that
have been observed, considering that a relation between the
development of symptoms (mostly related to neutropenia)
and the presence of STAT3 mutations has been reported16.
A previously unreported CLPD-NK leukemic clone
heterogeneity emerged thanks to the high sequencing
depth and the use of variant calling methods suitable to
detect low VAF somatic mutations. Despite the stringent
Fig. 3 Summary of most relevant genes somatically mutated in CLPD-NK: functions and putative drivers. a KEGG and Reactome pathway-
derived network of somatic mutations detected in CLPD-NK, by WES (circles) and by STAT3 targeted screening (triangle); direct, indirect and predicted
relations between genes and gene products annotated in pathways topologies are shown; node colors indicate different groups of pathways and
functions, according to the table in panel (b); circular node size is proportional to the evaluation of possible driver role considering mutation VAF and
predicted impact and gene function and expression; b Genes involved in different groups of pathways mutated in each patient highlight functions
recurrently hit in different patients (gene name in bold, VAF ≥ 0.1; bold and underlined VAF ≥ 0.2).
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variant filtering used, an average of 87 deleterious and
population rare somatic variants per patient were present.
Most (80%) of these variants were highly subclonal (VAF
< 0.05) and could be in part due to clonal hematopoiesis,
relatively common in elderly people37. Higher VAF
mutations, more deeply investigated here, corresponded
to 217 SNPs and 18 indels, in 226 genes, in the whole
cohort. Mutations with VAF > 0.2 were present in almost
all patients: in 15 different genes in patient #165 and from
1 to 7 different genes in other 11 patients. Only in patient
#117 the three most prominent variants had all a relatively
low VAF (0.14–0.1), with a missense variant of the
oncogene ARAF being the most prominent. Of the two
patients who required treatment, #187 presented variants
with VAF at least 0.2 in 6 genes, including the chromatin
regulator RSF1 that carried a validated deleterious mis-
sense variant in the DNA-binding domain (Table 2),
whereas patient #448 had only subclonal variants.
Notwithstanding the relatively high number of somatic
variants in the CLPD-NK cohort, only six genes were
mutated in at least two patients and for four of them a
primary drivers role was not supported by the relatively
low VAF and expression. Function, expression, previous
evidence of involvement in hematological malignancies
and variant VAF indicated TET2 as the most notable
mutated gene. Two patients carried truncating mutations
that eliminate the C-terminal Oxygenase catalytic domain
of TET2, an epigenetic and transcriptional regulator
involved in DNA demethylation critical for immune
homeostasis35 (Fig. 3b). TET2 alterations were associated
with development of myeloid38 and lymphoid39 malig-
nancies, and a TET2 truncating variant was observed in
one ANKL case11. The validated loss-of-function TET2
truncating variant was associated with a particularly high
mutation burden in patient #165. The relatively young age
of the patient (45 years) argues against clonal hemato-
poiesis as an explanation for such a high VAF TET2
mutation present in the leukemic clone37. Importantly, in
light of recent evidence of the role of TET2 in main-
tenance of genome stability35, the high mutation burden
observed by WES in patient #165, backed up by validation
of deleterious variants of 6 genes (DDX3X, EFEMP1,
MPZL1, CFH, RXRG, and SALL1), supports the driver role
of TET2 variant.
The pathogenetic relevance of JAK/STAT pathway muta-
tions in T-LGLL is well established3,9,10 with a markedly high
prevalence in patients. JAK/STAT mutations or amplifica-
tions were shown to be involved in ANKL11 and NKTCL12 as
well, although with a lower prevalence as compared to T-
LGLL. Genes of the JAK/STAT pathway reported to be
associated to CLPD-NK (STAT3, STAT5B, and JAK3)14,15
were not mutated in the 13 patients analyzed by WES.
Mutations of TNFAIP315, previously found in CLPD-NK,
were not detected in our cohort. Anyhow, deleterious
variants in STAT interactors or genes annotated in the JAK/
STAT pathway (PTK2/FAK1 and PIK3R1) were present
in two patients (15%) and can be regarded as primary drivers
in these cases (Fig. 3). PIK3R1 recurrent mutation in
lymphoid malignancies40, with two mutational hotspot
regions observed, and severe risk of transformation in
BCR-ABL models by PIK3R1 deletion41 directly implicate
PIK3R1 hyperactivation in leukemogenesis. The PIK3R1
p.Ser565_Ile566insGluTyrArgGluIleAspLysArgMetAsnSer
variant falls in a protein region previously shown to be at the
interface with the C2 domain of catalytic subunit PIK3CA.
Mutations in this region (e.g., aa 567) abrogate the negative
regulation on PIK3CA, thereby promoting cell survival, Akt
activation and oncogenesis42,43. PIK3R1 is also involved in
the regulation of apoptosis, as other genes carrying deleter-
ious variants confirmed in this study: TNFRSF1A (Tumor
necrosis factor receptor superfamily member 1A), encoding a
subunit of a receptor whose activation triggers Caspase-8 and
apoptosis also involved in Interleukin and TNF signaling,
carried a validated p.Pro102Arg variant (VAF 0.34) in the
second TNFR domain of the extracellular portion of the
protein; TAOK2 (TAO Kinase 2), an effector of caspase 8
involved in apoptosis induction, in DNA damage response
and stress-activated MAPK cascade, carried a p.Val244Met
variant (VAF 0.25) in the kinase domain (Table 2). Of note,
three putative driver mutations (in PIK3R1, TAOK2, and
TNFRSF1A) at comparable VAF were identified and vali-
dated in patient #115.
Key clues of the possible relevance of deleterious
somatic mutations in CLPD-NK proteins were obtained
leveraging systems genetics approaches. The pathway and
protein-protein interaction network of CLPD-NK somatic
mutations (Fig. 3a) was reconstructed to obviate the low
recurrence at gene level and to discover if different but
functionally connected genes were hit by mutations in
different patients or by mutations co-occurring in the
same clone. A group of 28 genes mutated in all CLPD-NK
belonged to Ras/MAPK and PI3K-AKT signaling path-
ways, highly interconnected and associated with cancer
proliferation, survival, and migration.
Collectively, our analysis of mutation recurrence, VAF
and effect, and of gene function, involvement in pathways
and interactions and expression, identified a restricted
number of genes with a putative driver role, whose var-
iants were amongst those validated. In a personalized and
precision medicine perspective, a search in the Drug Gene
Interaction Database, identified that for at least six of the
genes with validated variants (RPS6KA1, PIK3R1, TAOK2,
TNFRSF1A, and TET2) one or more FDA-approved drugs
are already available (Table 2). For instance, cyclopho-
sphamide interacts with TNFRSF1A and is already used in
clinical management of T-LGLL as first line of treat-
ment44, whereas hypomethylating agents (azacitidine and
decitabine) are used to counteract TET2 loss of function,
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in myeloproliferative disorders45 and the CDK inhibitor
purvalanol A was shown to interact with RPS6KA146.
Finally, our results informed on similarities and differ-
ences between CLPD-NK and other LGL lymphoproli-
ferative diseases. Comparing the genetic landscapes of
CLPD-NK and T-LGLL (near CLPD-NK in the 2017
WHO classification of mature T- and NK-cell neoplasms),
possibly due to the limited size of both cohorts, a very
limited overlap of genes and pathways was found. Ras/
MAPK involvement3, however, common in several differ-
ent malignancies, emerged in both neoplasms. By com-
paring diseases of mature NK cells, similarities emerged
between the indolent CLPD-NK and the remarkably more
aggressive ANKL and NKTCL. Commonly mutated genes
had often a likely a driver role in CLPD-NK. TET2 trun-
cating variants were detected in CLPD-NK (2/13) and
ANKL (1/14) and different SET Domain containing epi-
genetic modifiers were mutated in both diseases (SETD1A
and SETD1B in CLPD-NK, SETD2 in ANKL). DDX3X
mutation, recurrent in ANKL11 and in NKTCL47, was
observed here for the first time in CLPD-NK. Other genes
mutated both in CLPD-NK and ANKL patients included
DDX11, RSF1, and KRAS. Tyrosine phosphatase mutations
were reported in ANKL and are considered a hallmark of
NKTCL, whereas in our CLPD-NK cohort only one tyr-
osine phosphatase (PTPRN) was mutated. In ANKL and
NKTCL a high Epstein Barr Virus (EBV) burden was
previously detected11 by WES data analysis by Cen-
trifuge48. At variance, our analysis performed with the
same approach did not detect any EBV load in CLPD-NK
patients (data not shown).
Our data confirmed a possible involvement in CLPD-
NK of the JAK/STAT pathway, even though not directly
since somatic mutations hit genes whose primary function
is implicated in other signaling pathways. Of novelty, we
showed that somatic mutations of CLPD-NK patient
leukemic clones affect genes of the Ras/MAPK and PI3K
pathways involved in cancer proliferation, survival and
migration, or cell cycle, DNA repair and epigenetic reg-
ulator genes. This study broadened our knowledge of the
CLPD-NK leukemic clone genetic profile in patients
negative for STAT3/5B mutations, giving relevant new
insights into the pathobiology of CLPD-NK and opening
new possibilities for personalized treatment of patients.
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